Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002681 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
A Phase 1 study, sponsored by Roger Williams Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00002681: Completed Phase 1 study, sponsored by Roger Williams Medical Center.
NCT00002681 is a Phase 1 study that has completed, run by Roger Williams Medical Center. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002681, a Phase 1 study, has completed, sponsored by Roger Williams Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1995-07 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
What the finished NCT00002681 record still lists
NCT00002681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00002681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002681 about?
NCT00002681 is a clinical study titled "Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective trea...
What is the current status of trial NCT00002681?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1995-07. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00002681?
The interventions under investigation include: aldesleukin (BIOLOGICAL), daclizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002681?
This trial is sponsored by Roger Williams Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002681's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia